SCHEMBL24658331

SCHEMBL24658331

C=CCc1cc(C(=O)CCc2nc(-c3ccc(Cl)cc3Cl)oc2C(C)C)ccc1OCCO

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.46
PPARA Q07869 3/20 0.46
PPARD Q03181 2/20 0.46
KDM4E B2RXH2 10/20 0.41
LMNA P02545 2/20 0.39
NPSR1 Q6W5P4 1/20 0.38
MAPT P10636 2/20 0.38
THRB P10828 1/20 0.38
ALDH1A1 P00352 6/20 0.37
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
PTGDR Q13258 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
NPC1 O15118 1/20 0.35
POLB P06746 1/20 0.35
TSHR P16473 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30003957 1.00 PPARG (0.46) PPARGPPARAPPARDKDM4ELMNA
SCHEMBL2466958 0.93 PPARG (0.44) PPARGPPARAPPARDKDM4ELMNA
SCHEMBL12732395 0.91 PPARG (0.49) PPARGPPARAPPARDKDM4ELMNA
SCHEMBL2467711 0.91 PPARG (0.56) PPARGPPARAPPARDKDM4ELMNA
SCHEMBL4811284 0.89 PPARG (0.45) PPARGPPARAPPARDKDM4ENPSR1
SCHEMBL24742416 0.89 PPARA (0.50) PPARGPPARAPPARDLMNAMAPT
SCHEMBL30004652 0.89 PPARA (0.50) PPARGPPARAPPARDLMNAMAPT
SCHEMBL24658335 0.88 PPARA (0.55) PPARGPPARAPPARDKDM4ELMNA
SCHEMBL30003540 0.88 PPARA (0.55) PPARGPPARAPPARDKDM4ELMNA
SCHEMBL2466956 0.87 PPARG (0.43) PPARGPPARAPPARDKDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278952-A1 Compounds Useful for Treating Liver Diseases ABIONYX PHARMA SA (FR) 2023-09-07 US disclosed
US-20230278952-A1 Compounds Useful for Treating Liver Diseases ABIONYX PHARMA SA (FR) 2023-09-07 US disclosed
US-20220363632-A1 Compounds Useful for Treating Liver Diseases ABIONYX PHARMA SA (FR) 2022-11-17 US disclosed
WO-2022189856-A9 COMPOUNDS USEFUL FOR TREATING LIVER DISEASES ABIONYX PHARMA SA (FR) 2022-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278952-A1 Compounds Useful for Treating Liver Diseases SLC10A1, FABP1, CPT1A PPARG 71/4885PPARA 94/4885PPARD 332/4885
US-20220363632-A1 Compounds Useful for Treating Liver Diseases SLC10A1, FABP1, CPT1A PPARG 71/4885PPARA 94/4885PPARD 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.